Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  BRCA1 mutation carrier
Stage/Subtype:  BRCA1 mutation carrier
Results 1-25 of 26 for your search:
Start Over
Metformin Hydrochloride in Preventing Breast Cancer in Patients with Atypical Hyperplasia or In Situ Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 25 to 55
Trial IDs: A211102, NCI-2013-00995, CALGB-A211102, NCT01905046
A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: PR-30-5010-C, NCI-2014-00678, 1307-BCG, 1307-BCG, BIG5-13, NCT01905592
A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: 673-301, NCI-2014-00659, U1111-1155-7579, NCT01945775
Olaparib in Treating Patients with Triple-Negative Non-metastatic Breast Cancer Who Have Completed Definitive Local Treatment and Chemotherapy
Phase: Phase III
Type: Natural history/Epidemiology, Treatment
Age: 18 and over
Trial IDs: NSABP-B-55, NCI-2014-00644, BIG 6-13, D081CC00006, NCT02032823
Olaparib in gBRCA Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: D081FC00001, NCI-2015-00038, 2014-001589-85, NCT02184195
Olaparib or Cediranib Maleate and Olaparib Compared with Standard Platinum-Based Chemotherapy in Treating Patients with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Health services research, Treatment
Age: Not specified
Trial IDs: NRG-GY004, NCI-2015-00606, NCT02446600
MEDI4736 and Olaparib or Cediranib Maleate in Treating Patients with Advanced Solid Tumors or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-C-0145, NCI-2015-01401, 344406, P141726, NCT02484404
Gemcitabine Hydrochloride and Cisplatin with or without Veliparib or Veliparib Alone in Patients with Locally Advanced or Metastatic Pancreatic Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-045, NCI-2012-00864, CDR0000732189, MSKCC-12-045, 8993, NCT01585805
Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy
Phase: Phase II
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: NCI 2013-01-03, NCI-2014-02412, HHSN2612201200035I, N01-CN-2012-00035, NWU2013-01-03, NCT02314156
Veliparib and Dinaciclib with or without Carboplatin in Treating Patients with Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 11-144, NCI-2011-03458, CDR0000710900, DFCI-11-144, 8484, NCT01434316
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NCI 9782, NCI-2014-02474, 9782, NCT02317874
Talazoparib, Carboplatin, and Paclitaxel in Treating Patients with Advanced Solid Tumors and BRCA Mutations or Triple-Negative Metastatic Breast Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CC #14955, NCI-2015-00713, 130847, 14955, NCT02358200
Studying Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 to 80
Trial IDs: GOG-8008, NCI-2009-00615, CDR0000598427, NCT00897455
BRCA1 and BRCA2 Mutations and Triple Negative Disease in Hispanic/Latino Patients with Breast Cancer
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 18 and over
Trial IDs: 11-C-N035, NCI-2015-01247, 308834, P10629, NCT01251900
Compliance Rate of Delayed Oophorectomy in Patients with BRCA Gene Mutation Undergoing Salpingectomy
Phase: No phase specified
Type: Prevention, Screening
Age: 35 to 46
Trial IDs: 2013-0340, NCI-2015-00465, NCT01907789
Diffusion-Weighted MRI in Imaging Patients at High Risk for Breast Cancer
Phase: No phase specified
Type: Screening
Age: 21 and older
Trial IDs: LCCC1236, NCI-2014-02425, 12-2327, NCT01938157
Curcumin in Reducing Inflammatory Changes in Breast Tissue in Obese Patients At High Risk for Breast Cancer
Phase: No phase specified
Type: Prevention
Age: 19 and over
Trial IDs: OSU-13034, NCI-2013-01199, 2013C0039, NCT01975363
Biomarker Analysis in Improving Screening in Patients with or at High Risk of Developing Pancreatic Cancer
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: J1394, NCI-2014-01695, NA_00087754 / CIR00003036, NCT02000089
Early Changes in Breast Duct Cells and Gene Expression Profile in Patients with or at High Risk for Breast Cancer and Healthy Participants
Phase: No phase specified
Type: Natural history/Epidemiology
Age: Any age
Trial IDs: 02-C-0077, NCI-2013-02028, 020077, NCT00070460, NCT00028340
Energy Balance Interventions in Increasing Physical Activity in Cancer Survivors or High-Risk Family Members
Phase: No phase specified
Type: Prevention
Age: 18 and over
Trial IDs: 2014-0230, NCI-2015-00095, NCT02194387
Start Over